

## 6. References

1. Melzack R, Wall PD. Pain mechanisms: A new theory. *Science* 1965; 150:971-979.
2. Millan MJ. Multiple opioid systems and pain. *Pain* 1986; 27:303-347.
3. Stein C. Mechanisms of disease: the control of pain in peripheral tissue by opioids. *New England Journal of Medicine* 1995; 332:1685-90.
4. Machelska H, Stein C. Immune mechanisms in pain control. *Anesth Analg* 2002; 95:1002-8, table of contents.
5. Stein C, Millan MJ, Shippenberg TS, Herz A. Peripheral effect of fentanyl upon nociception in inflamed tissue of the rat. *Neurosci Lett* 1988; 84:225-8.
6. Stein C, Millan MJ, Shippenberg TS, Peter K, Herz A. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. *J Pharmacol Exp Ther* 1989; 248:1269-75.
7. Stein C. Peripheral mechanisms of opioid analgesia. *Anesth Analg* 1993; 76:182-91.
8. Fields HL, Emson PC, Leigh BK, Gilbert RF, Iversen LL. Multiple opiate receptor sites on primary afferent fibres. *Nature* 1980; 284:351-3.
9. Stein C, Hassan AH, Przewlocki R, Gramsch C, Peter K, Herz A. Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. *Proc Natl Acad Sci U S A* 1990; 87:5935-9.
10. Zhou L, Zhang Q, Stein C, Schäfer M. Contribution of opioid receptors on primary afferent versus sympathetic neurons to peripheral opioid analgesia. *J Pharmacol Exp Ther* 1998; 286:1000-6.
11. Stein C, Pflüger M, Yassouridis A, Hoelzl, J, Lehrberger, K, Welte, C, Hassan, AHS. No tolerance to peripheral morphine analgesia in the presence of opioid expression in inflamed synovia. *J Clin Invest* 1996; 98:793-799.
12. Stein C, Machelska H, Schäfer M. Peripheral analgesic and antiinflammatory effects of opioids. *Z Rheumatol* 2001; 60:416-24.
13. Hassan AH, Ableitner A, Stein C, Herz A. Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. *Neuroscience* 1993; 55:185-95.

14. Jiang M, et al. Multiple neurological abnormalities in mice deficient in the G-protein G<sub>0</sub>. *Proc Natl Acad Sci U S A* 1998; 95:3269-74.
15. Borgland SL, Connor M, Christie MJ. Nociception inhibits calcium channel currents in a subpopulation of small nociceptive trigeminal ganglion neurons in mouse. *J Physiol* 2001; 536:35-47.
16. Schäfer M, Imai Y, Uhl GR, Stein C. Inflammation enhances peripheral mu-opioid receptor-mediated analgesia, but not mu-opioid receptor transcription in dorsal root ganglia. *Eur J Pharmacol* 1995; 279:165-9.
17. Ji R-R, et al. Expression of mu-, delta- and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. *The Journal of Neuroscience* 1995; 15:8156-8166.
18. Zhang Q, Schäfer M, Elde R, Stein C. Effects of neurotoxins and hindpaw inflammation on opioid receptor immunoreactivities in dorsal root ganglia. *Neuroscience* 1998; 85:281-291.
19. Mousa SA, Zhang Q, Sitte N, Ji R, Stein C. beta-Endorphin-containing memory-cells and mu-opioid receptors undergo transport to peripheral inflamed tissue. *J Neuroimmunol* 2001; 115:71-8.
20. Stein C, Schäfer M, Cabot PJ. Peripheral opioid analgesia. *Pain Rev.* 1997; 4:171-85.
21. Sharp BM. Opioid receptor expression and intracellular signalling by cells involved in host defence and immunity. In: Machelska H, Stein C, eds. *Immune mechanisms of pain and analgesia*. Georgetown, TX: Landes Bioscience, 2002:98-103.
22. Carr DJ. The role of endogenous opioids and their receptors in the immune system. *Proc Soc Exp Biol Med* 1991; 198:710-20.
23. Höllt V. Opioid peptide processing and receptor selectivity. *Annu Rev Pharmacol Toxicol* 1986; 26:59-77.
24. Zadina JE, Hackler L, Ge L-J, Kastin AJ. A potent and selective endogenous agonist for the  $\mu$ -opiate receptor. *Nature* 1997; 386:499-502.
25. Blalock JE. The syntax of immune-neuroendocrine communication. *Immunol Today* 1994; 15:504-11.

26. Smith EM. Opioid peptides in immune cells. In: Machelska H, Stein C, eds. Immune mechanisms of pain and analgesia. Georgetown, TX: Landes Bioscience, 2002:51-63.
27. Ottaviani E, Franchini A, Franceschi C. Pro-opiomelanocortin-derived peptides, cytokines, and nitric oxide in immune responses and stress: an evolutionary approach. *Int Rev Cytol* 1997; 170:79-141.
28. Jessop DS, Major GN, Coventry TL, Kaye SJ, Fulford AJ, Harbuz MS, De Bree FM. Novel opioid peptides endomorphin-1 and endomorphin-2 are present in mammalian immune tissues. *J Neuroimmunol* 2000; 106:53-9.
29. Linner KM, Quist HE, Sharp BM. Expression and function of proenkephalin A messenger ribonucleic acid in murine fetal thymocytes. *Endocrinology* 1996; 137:857-63.
30. Weisinger G. The transcriptional regulation of the preproenkephalin gene. *Biochem J* 1995; 307 ( Pt 3):617-29.
31. Przewlocki R, Hassan AH, Lason W, Eppelen C, Herz A, Stein C. Gene expression and localization of opioid peptides in immune cells of inflamed tissue: functional role in antinociception. *Neuroscience* 1992; 48:491-500.
32. Hassan AH, Pzewlocki R, Herz A, Stein C. Dynorphin, a preferential ligand for kappa-opioid receptors, is present in nerve fibers and immune cells within inflamed tissue of the rat. *Neurosci Lett* 1992; 140:85-8.
33. Mousa SA, Machelska H, Schäfer M, Stein C. Immunohistochemical localization of endomorphin-1 and endomorphin-2 in immune cells and spinal cord in a model of inflammatory pain. *J Neuroimmunol* 2002; 126:5-15.
34. Cabot PJ, Carter L, Gaiddon C, Zhang Q, Schafer M, Loeffler JP, Stein C. Immune cell-derived beta-endorphin. Production, release, and control of inflammatory pain in rats. *J Clin Invest* 1997; 100:142-8.
35. Cabot PJ, Carter L, Schäfer M, Stein C. Methionine-enkephalin-and Dynorphin A-release from immune cells and control of inflammatory pain. *Pain* 2001; 93:207-12.
36. Parsons CG, Czlonkowski A, Stein C, Herz A. Peripheral opioid receptors mediating antinociception in inflammation. Activation by endogenous opioids and role of the pituitary-adrenal axis. *Pain* 1990; 41:81-93.

37. Khodorova A, Navarro B, Jouaville LS, Murphy JE, Rice FL, Mazurkiewicz JE, Long-Woodward D, Stoffel M, Strichartz GR, Yukhananov R, Davar G. Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. *Nat Med* 2003; 9:1055-1061.
38. Stein C, Machelska H. Pain control by immune-derived opioids. *Clin Exp Pharmacol Physiol* 2000; 27:533-536.
39. Braz J, Beaufour C, Coutaux A, Epstein AL, Cesselin F, Hamon M, Pohl M. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. *J Neurosci* 2001; 21:7881-8.
40. Veihelmann A, Harris AG, Krombach F, Schutze E, Refoir HJ, Messmer K. In vivo assessment of synovial microcirculation and leukocyte-endothelial cell interaction in mouse antigen-induced arthritis. *Microcirculation* 1999; 6:281-190.
41. Brown E. Neutrophil adhesion and the therapy of inflammation. *Semin Hematol* 1997; 34:319-26.
42. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. *Science* 1996; 272:60-6.
43. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. *Cell* 1994; 76:301-14.
44. Von Adrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. *N Engl J Med* 2000; 343:1020-34.
45. Issekutz AC. Adhesion molecules mediating neutrophil migration to arthritis in vivo and across endothelium and connective tissue barriers in vitro. *Inflamm Res* 1998; 47 Suppl 3:S123-32.
46. Walter UM, Issekutz AC. The role of E- and P-selectin in neutrophil and monocyte migration in adjuvant-induced arthritis in the rat. *Eur J Immunol* 1997; 27:1498-505.
47. Issekutz AC, Issekutz TB. The role of E-selectin, P-selectin, and very late activation antigen-4 in T lymphocyte migration to dermal inflammation. *J Immunol* 2002; 168:1934-9.

48. Issekutz AC, Issekutz TB. Monocyte migration to arthritis in the rat utilizes both CD11/CD18 and very late activation antigen 4 integrin mechanisms. *J Exp Med* 1995; 181:1197-203.
49. Issekutz TB, Miyasaka M, Issekutz AC. Rat blood neutrophils express very late antigen 4 and it mediates migration to arthritic joint and dermal inflammation. *J Exp Med* 1996; 183:2175-84.
50. Seiffge D. Protective effects of monoclonal antibody to VLA-4 on leukocyte adhesion and course of disease in adjuvant arthritis in rats. *J Rheumatol* 1996; 23:2086-2091.
51. Issekutz AC, Ayer L, Miyasaka M, Issekutz TB. Treatment of established adjuvant arthritis in rats with monoclonal antibody to CD18 and very late activation antigen-4 integrins suppresses neutrophil and T-lymphocyte migration to the joints and improves clinical disease. *Immunology* 1996; 88:569-76.
52. Issekutz AC, Mu JY, Liu G, Melrose J, Berg EL. E-selectin, but not P-selectin, is required for development of adjuvant-induced arthritis in the rat. *Arthritis Rheum* 2001; 44:1428-37.
53. Ihsikaw J, Okada Y, Bird IN, Jasani B, Spragg JH, Yamada T. Use of anti-platelet-endothelial adhesion molecule-1 antibody in the control of disease progression in established collagen-induced arthritis in DBA/1J mice. *Jpn J Pharmacol* 2002; 88:332-340.
54. van de Langerijt AG, Mobley JM, Justen JM, et al. Role of beta 2 integrins in the recruitment of pathogenic cells in joint inflammation in the rat. *Clin Immunol Immunopathol* 1999; 73:123-131.
55. Bullard DC, Mobley JM, Justen JM, Sly LM, Chosay, JG, Dunn CJ, Lindsey JR, Beaudet AL, Staite ND. Acceleration and increased severity of collagen-induced arthritis in P-selectin mutant mice. *J Immunol* 1999; 163:2844-9.
56. Mousa SA, Machelska H, Schäfer M, Stein C. Co-expression of beta-endorphin with adhesion molecules in a model of inflammatory pain. *J Neuroimmunol* 2000; 108:160-70.
57. Machelska H, Cabot PJ, Mousa SA, Zhang Q, Stein C. Pain control in inflammation governed by selectins. *Nat Med* 1998; 4:1425-8.

58. Rittner HL, Brack A, Machelska H, Mousa SA, Bauer M, Schäfer M, Stein C. Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. *Anesthesiology* 2001; 95:500-8.
59. Munck A, Guyre PM, Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. *Endocr Rev* 1984; 5:25-44.
60. Croffort LJ, Sano H, Karalis K, Webster EA, Goldmuntz GP, Chrousos GP, Wilder RL. Local secretion of corticotropin-releasing hormone in the joints of Lewis rats with inflammatory arthritis. *J Clin Invest* 1992; 90:2555.
61. Karalis K, Sano H, Redwine J, Listwak S, Wilder RL, Chrousos GP. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. *Science* 1991; 254:421-3.
62. Schäfer M, Mousa SA, Stein C. Corticotropin-releasing factor in antinociception and inflammation. *Eur J Pharmacol* 1997; 323:1-10.
63. Mousa SA, Schäfer M, Mitchell WM, Hassan AH, Stein C. Local upregulation of corticotropin-releasing hormone and interleukin-1 receptors in rats with painful hindlimb inflammation. *Eur J Pharmacol* 1996; 311:221-31.
64. Schäfer M, Carter L, Stein C. Interleukin 1 beta and corticotropin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue. *Proc Natl Acad Sci U S A* 1994; 91:4219-23.
65. Terman GW, Shavit Y, Lewis JW, Cannon JT, Liebeskind JC. Intrinsic mechanisms of pain inhibition: activation by stress. *Science* 1984; 226:1270-7.
66. Rubinstein M, Mogil JS, Japon M, Chan EC, Allen RG, Low MJ. Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis. *Proc Natl Acad Sci U S A* 1996; 93:3995-4000.
67. Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. *Annu Rev Neurosci* 1984; 7:309-38.
68. Mansour A, Fox CA, Burke S, Akil H, Watson SJ. Immunohistochemical localization of the cloned mu opioid receptor in the rat CNS. *J Chem Neuroanat* 1995; 8:283-305.

69. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. *Trends Neurosci* 1995; 18:22-9.
70. Stein C, Gramsch C, Herz A. Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and beta-endorphin. *J Neurosci* 1990; 10:1292-8.
71. Stein C, Hassan AH, Lehrberger K, Giefing J, Yassouridis A. Local analgesic effect of endogenous opioid peptides. *Lancet* 1993; 342:321-4.
72. Schäfer M, Mousa SA, Zhang Q, Carter L, Stein C. Expression of corticotropin-releasing factor in inflamed tissue is required for intrinsic peripheral opioid analgesia. *Proc Natl Acad Sci U S A* 1996; 93:6096-100.
73. Machelska H, Stein C. Pain control by immune-derived opioids. *Clin Exp Pharmacol Physiol* 2000; 27:533-6.
74. Hamann A, Andrew D, Jablonski-Westrich D, Holzmann B, Butcher E. Role of alpha-4 integrins in lymphocyte homing to mucosal tissue in vivo. *J Immunol* 1994; 152:3282-3293.
75. Millan MJ, Czlonkowski A, Morris B, Stein C, Arendt R, Huber A, Holtt V, Herz A. Inflammation of the hind limb as a model of unilateral, localized pain: influence on multiple opioid systems in the spinal cord of the rat. *Pain* 1988; 35:299-312.
76. Stein C, Miller MJ, Herz A. Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation, alterations in behavior and nociceptive thresholds. *Pharmacol Biochem Behav* 1988; 31: 445 - 451.
77. Shannon HE, Lutz EA. Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats. *Neuropharmacology* 2002; 42:253-61.
78. Singer AJ, Clark RA. Cutaneous wound healing. *N Engl J Med* 1999; 341:738-46.
79. Westermann J, Pabst R. How organ-specific is the migration of 'naive' and 'memory' T cells? *Immunol Today* 1996; 17:278-82.

80. Machelska H, Schopohl JK, Mousa SA, Labuz D, Schäfer M, Stein C. Different mechanisms of intrinsic pain inhibition in early and late inflammation. *J Neuroimmunol* 2003; 141:30-39.
81. Starec M, Rosina J, Malek J, Krsiak M. Influence of dynorphin A (1-13) and dynorphin A (1-10) amide on stress-induced analgesia. *Physiol Res* 1996; 45:433-8.
82. Nabeshima T, Yamada T, Kameyama T. Contribution of different opioid systems to footshock-induced analgesia and motor suppression. *Eur J Pharmacol* 1983; 92:199-205.
83. Jordan BA, Cvejic S, Devi LA. Opioids and their complicated receptor complexes. *Neuropsychopharmacology* 2000; 23:S5-S18.
84. Devi LA, Brady LS. Dimerization of G-protein coupled receptors. *Neuropsychopharmacology* 2000; 23:S3-4.
85. Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA. Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. *J Neurosci* 2000; 20:RC110.
86. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. *Nature* 1999; 399:697-700.
87. Pliska V. Models to explain dose-response relationships that exhibit a downturn phase. *Trends Pharmacol Sci* 1994; 15:178-81.
88. Kolesnikov YA, Jain S, Wilson R, Pasternak GW. Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance. *J Pharmacol Exp Ther* 1996; 279:502-6.
89. Schmitt TK, Mousa SA, Brack A, Schmitt DK, Rittner HL, Welte M, Schäfer M, Stein C. Modulation of peripheral endogenous opioid analgesia by central afferent blockade. *Anesthesiology* 2003; 98:195-202.
90. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. *N Engl J Med* 2000; 343:1020-34.
91. Nelson R, Cecconi O, Roberts W, Aruffo A, Linhardt R, Bevilacqua M. Heparin Oligosaccharides Bind L- and P-Selectin and Inhibit Acute Inflammation. *Blood* 1993; 82:3253-3258.



92. Clayton A, Evans RA, Pettit E, Hallett M, Williams JD, Steadman R. Cellular activation through the ligation of intercellular adhesion molecule-1. *J Cell Sci* 1998; 111 ( Pt 4):443-53.
93. Vuorte J, Lindsberg PJ, Kaste M, Meri S, Jansson SE, Rothlein R, Repo H. Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood. *J Immunol* 1999; 162:2353-7.
94. Willenborg DO, Simmons RD, Tamatani T, Miyasaka M. ICAM-1-dependent pathway is not critically involved in the inflammatory process of autoimmune encephalomyelitis or in cytokine-induced inflammation of the central nervous system. *J Neuroimmunol* 1993; 45:147-54.
95. Bach JF, Fracchia GN, Chatenoud L. Safety and efficacy of therapeutic monoclonal antibodies in clinical therapy. *Immunol Today* 1993; 14:421-5.
96. McCafferty D-M, Smith CW, Granger DN, Kubes P. Intestinal inflammation in adhesion-molecule deficient mice: an assessment of P-selectin alone and in combination with ICAM-1 or E-selectin. *Journal of Leukocyte Biology* 1999; 66:July.
97. Machelska H, Mousa SA, Brack A, Schopohl JK, Rittner HL, Schäfer M, Stein C. Opioid control of inflammatory pain regulated by intercellular adhesion molecule-1. *J Neurosci* 2002; 22:5588-96.
98. Beekhuizen H, Blokland I, van Furth R. Cross-linking of CD14 molecules on monocytes results in a CD11/CD18- and ICAM-1-dependend adherence to cytokine-stimulated human endothelial cells. *J Immunol* 1993; 150:950-959.
99. Porter, JC, Hogg, N (1997). Integrin cross talk: activation of lymphocyte function-associated antigen-1 on human T cells alters alpha4beta1- and alpha5beta1-mediated function. *J Cell Biol* 1997; 138: 1437 – 1447).
100. Machelska H, Brack A, Mousa SA, Schopohl JK, Rittner HL, Schäfer M, Stein C. Selectins and integrins but not platelet-endothelial cell adhesion molecule-1 regulate opioid inhibition of inflammatory pain. *Br J Pharmacol* 2004; 142: 772 -780.
101. Sanchez-Madrid F, Nagy J, Robbins E, Simon P, Springer TA. A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1),

- the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule. *J Exp Med* 1983; 158:1785-1803.
102. Iigo Y, Takashi T, Tamatani T, Miyasaka M, Higashida T, Yagita H, Okumura K, Tsukada W. ICAM-1-dependent pathway is critically involved in the pathogenesis of adjuvant arthritis in rats. *J Immunol* 1991; 147:4167-4171.
  103. Kavanaugh A, Davis L, Nichols L, Norris SH, Rothlein R, Scharschmidt LA, Lipsky PE. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. *Arthritis Rheum* 1994; 37:992-999.
  104. Bennett CF, Kornbrust D, Henry S, Stecker K, Howard R, Cooper S, Dutson S, Hall W, Jacoby HI. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. *J Pharmacol Exp Ther* 1997; 280:988-1000.
  105. Birner U, Issekutz TB, Issekutz AC. The role of selectins in VLA-4 and CD18-independent neutrophil migration to joints of rats with adjuvant arthritis. *Eur J Immunol* 1999; 29:1094-100.
  106. Bullard DC, Hurley LA, Lorenzo I, Sly LM, Beaudet AL, Staite ND. Reduced susceptibility to collagen-induced arthritis in mice deficient in intercellular adhesion molecule-1. *J Immunol* 1996; 157:3153-3158.
  107. Shimada Y, Hasegawa M, Kaburagi Y, Hamaguchi Y, Komura K, Saito E, Takehara K, Steeber DA, Tedder F, Sato S. L-selectin or ICAM-1 deficiency reduces an immediate-type hypersensitivity response by preventing mast cell recruitment in repeated elicitation of contact hypersensitivity. *J Immunol* 2003; 170:4325-34.
  108. Tang T, Frenette PS, Hynes RO, Wagner DD, Mayadas TN. Cytokine-induced meningitis is dramatically attenuated in mice deficient in endothelial selectins. *J Clin Invest* 1996; 97:2485-90.
  109. Samoilova E, Horton J, Chen Y. Experimental autoimmune encephalomyelitis in intercellular adhesion molecule-1 deficient mice. *Cell Immunol* 1998; 190:83-89.

110. Marvin M, Southall J, Trokhan S, DeRosa C, Chabot J. Liver metastasis are enhanced in homozygous deletionally mutant ICAM-1 or LFA-1 mice. *J Surg Res* 1998; 80:143-148.
111. Cunha FQ, Ferreira SH. Peripheral hyperalgesic cytokines. *Adv Exp Med Biol* 2003; 521:22-39.
112. Dray A, Urban L, Dickenson A. Pharmacology of chronic pain. *Trends Pharmacol Sci* 1994; 15:190-7.
113. Shu XQ, Mendell LM. Neurotrophins and hyperalgesia. *Proc Natl Acad Sci U S A* 1999; 96:7693-6.
114. Mogil JS, Grisel JE. Transgenic studies of pain. *Pain* 1998; 77:107-28.
115. Qiu C, Sora I, Ren K, Uhl G, Dubner R. Enhanced delta-opioid receptor-mediated antinociception in mu-opioid receptor-deficient mice. *Eur J Pharmacol* 2000; 387:163-9.
116. Stein C, Comisel K, Haimerl E, Yassouridis A, Lehrberger K, Herz A, Peter K. Analgesic effect of intraarticular morphine after arthroscopic knee surgery. *N Engl J Med* 1991; 325:1123-6.
117. Polydefkis MJ. Peripheral neuropathy and HIV. *Hopkins HIV Rep* 2002; 14:6-7.
118. Husstedt IW, Evers S, Reichelt D, Grotemeyer KH, Kammer-Suhr B, Bockenholt S, Heese C. Screening for HIV-associated distal-symmetric polyneuropathy in CDC-classification stages 1, 2, and 3. *Acta Neurol Scand* 2000; 101:183-7.
119. Hewitt DJ, McDonald M, Portenoy RK, Rosenfeld B, Passik S, Breitbart W. Pain syndromes and etiologies in ambulatory AIDS patients. *Pain* 1997; 70:117-23.
120. Pohl M, Braz J. Gene therapy of pain: emerging strategies and future directions. *Eur J Pharmacol* 2001; 429:39-48.